Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.

Hepatology (Baltimore, Md.) - 1 Jun 2026

Strain Rebecca, Edmans Matthew, Montalvo Zurbia-Flores Gerardo, Frumento Nicole, Brown Anthony, Hutchings Claire, Board Callum, Knight Chanice, Flyak Andrew I, Bailey Justin, Lauer Georg, Cox Andrea, Klenerman Paul, Barnes Eleanor

Abstract excerpt

BACKGROUND AND AIMS: An effective vaccine against hepatitis C virus (HCV) infection is required to achieve viral eradication. A previous viral vectored vaccine encoding a genotype-1b T cell antigen suppressed peak viral RNA but failed to prevent chronic infection. Previous studies showed dominant vaccine-induced T cell responses were not cross-reactive with common HCV strains, possibly contributing to vaccine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cross Reactions
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Immunization, Secondary

Share to Mice, Transgenic

Share to T-Lymphocytes

Share to Vaccinia virus

Share to Viral Hepatitis Vaccines

Source

Open in PubMed Open full text

Identifiers

PMID: 41236497
DOI: 10.1097/HEP.0000000000001599
PMCID: PMC13178782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.PMID 41236497Read ↗

Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.Semantic proximity Read ↗

A pan-genotype hepatitis C virus viral vector vaccine generates T cells and neutralizing antibodies in mice.Semantic proximity Read ↗

Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes.Semantic proximity Read ↗

The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.Semantic proximity Read ↗

Adenoviruses vectored hepatitis C virus vaccine cocktails induce broadly specific immune responses against multi-genotypic HCV in mice.Semantic proximity Read ↗

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.Semantic proximity Read ↗

Induction of Genotype Cross-Reactive, Hepatitis C Virus-Specific, Cell-Mediated Immunity in DNA-Vaccinated Mice.Semantic proximity Read ↗

Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity.Semantic proximity Read ↗

Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model.Semantic proximity Read ↗

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.Semantic proximity Read ↗

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.Semantic proximity Read ↗

A multi-genotype therapeutic human papillomavirus vaccine elicits potent T cell responses to conserved regions of early proteins.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.